Loading…
Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy
Purpose Monitoring circulating endothelial cells (CECs) count reflects the tumor vasculature in cancer patients and might be a predictor of response to chemotherapy. We therefore investigated the clinical significance of changes in CECs count after three cycles of platinum-based chemotherapy in pati...
Saved in:
| Published in: | Journal of cancer research and clinical oncology 2015-01, Vol.141 (1), p.119-125 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c442t-81ae9976973ae9826b19bf615e40970f72cf93953a69f302fce11060fd4184263 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c442t-81ae9976973ae9826b19bf615e40970f72cf93953a69f302fce11060fd4184263 |
| container_end_page | 125 |
| container_issue | 1 |
| container_start_page | 119 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 141 |
| creator | Najjar, Fadi Alammar, Moosheer Bachour, Marroan Almalla, Nissreen Altahan, Moaz Alali, Ali Al-Massarani, Ghassan |
| description | Purpose
Monitoring circulating endothelial cells (CECs) count reflects the tumor vasculature in cancer patients and might be a predictor of response to chemotherapy. We therefore investigated the clinical significance of changes in CECs count after three cycles of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Methods
Peripheral blood samples were collected from 89 naive NSCLC patients at diagnosis and after chemotherapy. The CECs were quantified by an immuno-magnetic technique and fluorescent microscopy. After chemotherapy, patients were assessed according to the response evaluation criteria in solid tumors as partial response (PR), stable disease (SD) or progression disease (PD).
Results
Baseline CECs levels were significantly higher in PR patients (
n
= 62) than those in patients with SD/PD (
n
= 27) (
p
= 0.0007). Although there was no significant correlation between baseline CECs levels and progression-free survival (PFS) (
p
= 0.287), patients with high percentage change in CECs count after chemotherapy had significantly longer PFS than those with low percentage change (
p
= 0.048). Regarding treatment efficacy, CECs count significantly decreased after chemotherapy in comparison with CECs count at baseline in patients with PR (
p
|
| doi_str_mv | 10.1007/s00432-014-1778-0 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1641718881</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3543830721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-81ae9976973ae9826b19bf615e40970f72cf93953a69f302fce11060fd4184263</originalsourceid><addsrcrecordid>eNp1kM9PHCEUx0nTpq62f0AvDYnnUR7MwMzRGKsmJnpoz4RlHrsYltkCY-O_4F9dNqONl56Ax_dH3oeQb8DOgDF1nhlrBW8YtA0o1TfsA1nBYQJCdB_JioGCpuMgj8hxzo-svjvFP5Mj3jGhAOSKvDwkHL0t_gmpiSPdp2kTp1y8pU8mzEgnR61Pdg6m-LihGMepbDF4E6jFEDL1kcYpNnlnwjKiYa5Ca6LFRPfVhrFkWhKagiP948uW5lK7TBqp3eLukJfM_vkL-eRMyPj19Twhv35c_by8ae7ur28vL-4a27a8ND0YHAYlByXqpedyDcPaSeiwZYNiTnHrBjF0wsjBCcadRQAmmRtb6FsuxQk5XXLrrr9nzEU_TnOKtVKDbCuyvu-hqmBR2TTlnNDpffI7k541MH2grxf6utLXB_qaVc_31-R5vcPxn-MNdxXwRZDrV9xgelf939S_Tm-RPQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1641718881</pqid></control><display><type>article</type><title>Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy</title><source>Springer Nature</source><creator>Najjar, Fadi ; Alammar, Moosheer ; Bachour, Marroan ; Almalla, Nissreen ; Altahan, Moaz ; Alali, Ali ; Al-Massarani, Ghassan</creator><creatorcontrib>Najjar, Fadi ; Alammar, Moosheer ; Bachour, Marroan ; Almalla, Nissreen ; Altahan, Moaz ; Alali, Ali ; Al-Massarani, Ghassan</creatorcontrib><description>Purpose
Monitoring circulating endothelial cells (CECs) count reflects the tumor vasculature in cancer patients and might be a predictor of response to chemotherapy. We therefore investigated the clinical significance of changes in CECs count after three cycles of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Methods
Peripheral blood samples were collected from 89 naive NSCLC patients at diagnosis and after chemotherapy. The CECs were quantified by an immuno-magnetic technique and fluorescent microscopy. After chemotherapy, patients were assessed according to the response evaluation criteria in solid tumors as partial response (PR), stable disease (SD) or progression disease (PD).
Results
Baseline CECs levels were significantly higher in PR patients (
n
= 62) than those in patients with SD/PD (
n
= 27) (
p
= 0.0007). Although there was no significant correlation between baseline CECs levels and progression-free survival (PFS) (
p
= 0.287), patients with high percentage change in CECs count after chemotherapy had significantly longer PFS than those with low percentage change (
p
= 0.048). Regarding treatment efficacy, CECs count significantly decreased after chemotherapy in comparison with CECs count at baseline in patients with PR (
p
< 0.0001). By contrast, CECs levels after chemotherapy were significantly higher than those at diagnosis in patients with PD (
p
= 0.002). Moreover, there was no significant change between pre- and post-treatment CECs amount in patients with SD (
p
= 0.681).
Conclusions
Baseline CECs levels might be an early predictive biomarker for treatment efficacy in advanced NSCLC patients. Our results suggest the change in CECs count after chemotherapy as a prognostic factor for tumor response and PFS in NSCLC.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-014-1778-0</identifier><identifier>PMID: 25037116</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject><![CDATA[Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers ; Biomarkers, Tumor - analysis ; Cancer Research ; Carboplatin - administration & dosage ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - pathology ; Chemotherapy ; Cisplatin - administration & dosage ; Clinical outcomes ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Endothelium ; Endothelium, Vascular - pathology ; Female ; Follow-Up Studies ; Hematology ; Humans ; Internal Medicine ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Staging ; Neoplastic Cells, Circulating - pathology ; Oncology ; Original Article – Clinical Oncology ; Prognosis ; Prospective Studies ; ROC Curve ; Survival Rate ; Taxoids - administration & dosage ; Vinblastine - administration & dosage ; Vinblastine - analogs & derivatives]]></subject><ispartof>Journal of cancer research and clinical oncology, 2015-01, Vol.141 (1), p.119-125</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-81ae9976973ae9826b19bf615e40970f72cf93953a69f302fce11060fd4184263</citedby><cites>FETCH-LOGICAL-c442t-81ae9976973ae9826b19bf615e40970f72cf93953a69f302fce11060fd4184263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25037116$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Najjar, Fadi</creatorcontrib><creatorcontrib>Alammar, Moosheer</creatorcontrib><creatorcontrib>Bachour, Marroan</creatorcontrib><creatorcontrib>Almalla, Nissreen</creatorcontrib><creatorcontrib>Altahan, Moaz</creatorcontrib><creatorcontrib>Alali, Ali</creatorcontrib><creatorcontrib>Al-Massarani, Ghassan</creatorcontrib><title>Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
Monitoring circulating endothelial cells (CECs) count reflects the tumor vasculature in cancer patients and might be a predictor of response to chemotherapy. We therefore investigated the clinical significance of changes in CECs count after three cycles of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Methods
Peripheral blood samples were collected from 89 naive NSCLC patients at diagnosis and after chemotherapy. The CECs were quantified by an immuno-magnetic technique and fluorescent microscopy. After chemotherapy, patients were assessed according to the response evaluation criteria in solid tumors as partial response (PR), stable disease (SD) or progression disease (PD).
Results
Baseline CECs levels were significantly higher in PR patients (
n
= 62) than those in patients with SD/PD (
n
= 27) (
p
= 0.0007). Although there was no significant correlation between baseline CECs levels and progression-free survival (PFS) (
p
= 0.287), patients with high percentage change in CECs count after chemotherapy had significantly longer PFS than those with low percentage change (
p
= 0.048). Regarding treatment efficacy, CECs count significantly decreased after chemotherapy in comparison with CECs count at baseline in patients with PR (
p
< 0.0001). By contrast, CECs levels after chemotherapy were significantly higher than those at diagnosis in patients with PD (
p
= 0.002). Moreover, there was no significant change between pre- and post-treatment CECs amount in patients with SD (
p
= 0.681).
Conclusions
Baseline CECs levels might be an early predictive biomarker for treatment efficacy in advanced NSCLC patients. Our results suggest the change in CECs count after chemotherapy as a prognostic factor for tumor response and PFS in NSCLC.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Cancer Research</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Clinical outcomes</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Endothelium</subject><subject>Endothelium, Vascular - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Oncology</subject><subject>Original Article – Clinical Oncology</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>ROC Curve</subject><subject>Survival Rate</subject><subject>Taxoids - administration & dosage</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - analogs & derivatives</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kM9PHCEUx0nTpq62f0AvDYnnUR7MwMzRGKsmJnpoz4RlHrsYltkCY-O_4F9dNqONl56Ax_dH3oeQb8DOgDF1nhlrBW8YtA0o1TfsA1nBYQJCdB_JioGCpuMgj8hxzo-svjvFP5Mj3jGhAOSKvDwkHL0t_gmpiSPdp2kTp1y8pU8mzEgnR61Pdg6m-LihGMepbDF4E6jFEDL1kcYpNnlnwjKiYa5Ca6LFRPfVhrFkWhKagiP948uW5lK7TBqp3eLukJfM_vkL-eRMyPj19Twhv35c_by8ae7ur28vL-4a27a8ND0YHAYlByXqpedyDcPaSeiwZYNiTnHrBjF0wsjBCcadRQAmmRtb6FsuxQk5XXLrrr9nzEU_TnOKtVKDbCuyvu-hqmBR2TTlnNDpffI7k541MH2grxf6utLXB_qaVc_31-R5vcPxn-MNdxXwRZDrV9xgelf939S_Tm-RPQ</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Najjar, Fadi</creator><creator>Alammar, Moosheer</creator><creator>Bachour, Marroan</creator><creator>Almalla, Nissreen</creator><creator>Altahan, Moaz</creator><creator>Alali, Ali</creator><creator>Al-Massarani, Ghassan</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20150101</creationdate><title>Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy</title><author>Najjar, Fadi ; Alammar, Moosheer ; Bachour, Marroan ; Almalla, Nissreen ; Altahan, Moaz ; Alali, Ali ; Al-Massarani, Ghassan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-81ae9976973ae9826b19bf615e40970f72cf93953a69f302fce11060fd4184263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Cancer Research</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Clinical outcomes</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Endothelium</topic><topic>Endothelium, Vascular - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Oncology</topic><topic>Original Article – Clinical Oncology</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>ROC Curve</topic><topic>Survival Rate</topic><topic>Taxoids - administration & dosage</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Najjar, Fadi</creatorcontrib><creatorcontrib>Alammar, Moosheer</creatorcontrib><creatorcontrib>Bachour, Marroan</creatorcontrib><creatorcontrib>Almalla, Nissreen</creatorcontrib><creatorcontrib>Altahan, Moaz</creatorcontrib><creatorcontrib>Alali, Ali</creatorcontrib><creatorcontrib>Al-Massarani, Ghassan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Najjar, Fadi</au><au>Alammar, Moosheer</au><au>Bachour, Marroan</au><au>Almalla, Nissreen</au><au>Altahan, Moaz</au><au>Alali, Ali</au><au>Al-Massarani, Ghassan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>141</volume><issue>1</issue><spage>119</spage><epage>125</epage><pages>119-125</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
Monitoring circulating endothelial cells (CECs) count reflects the tumor vasculature in cancer patients and might be a predictor of response to chemotherapy. We therefore investigated the clinical significance of changes in CECs count after three cycles of platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Methods
Peripheral blood samples were collected from 89 naive NSCLC patients at diagnosis and after chemotherapy. The CECs were quantified by an immuno-magnetic technique and fluorescent microscopy. After chemotherapy, patients were assessed according to the response evaluation criteria in solid tumors as partial response (PR), stable disease (SD) or progression disease (PD).
Results
Baseline CECs levels were significantly higher in PR patients (
n
= 62) than those in patients with SD/PD (
n
= 27) (
p
= 0.0007). Although there was no significant correlation between baseline CECs levels and progression-free survival (PFS) (
p
= 0.287), patients with high percentage change in CECs count after chemotherapy had significantly longer PFS than those with low percentage change (
p
= 0.048). Regarding treatment efficacy, CECs count significantly decreased after chemotherapy in comparison with CECs count at baseline in patients with PR (
p
< 0.0001). By contrast, CECs levels after chemotherapy were significantly higher than those at diagnosis in patients with PD (
p
= 0.002). Moreover, there was no significant change between pre- and post-treatment CECs amount in patients with SD (
p
= 0.681).
Conclusions
Baseline CECs levels might be an early predictive biomarker for treatment efficacy in advanced NSCLC patients. Our results suggest the change in CECs count after chemotherapy as a prognostic factor for tumor response and PFS in NSCLC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25037116</pmid><doi>10.1007/s00432-014-1778-0</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2015-01, Vol.141 (1), p.119-125 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_journals_1641718881 |
| source | Springer Nature |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomarkers, Tumor - analysis Cancer Research Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Chemotherapy Cisplatin - administration & dosage Clinical outcomes Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Endothelium Endothelium, Vascular - pathology Female Follow-Up Studies Hematology Humans Internal Medicine Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Neoplasm Staging Neoplastic Cells, Circulating - pathology Oncology Original Article – Clinical Oncology Prognosis Prospective Studies ROC Curve Survival Rate Taxoids - administration & dosage Vinblastine - administration & dosage Vinblastine - analogs & derivatives |
| title | Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A04%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20and%20prognostic%20value%20of%20circulating%20endothelial%20cells%20in%20non-small%20cell%20lung%20cancer%20patients%20treated%20with%20standard%20chemotherapy&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Najjar,%20Fadi&rft.date=2015-01-01&rft.volume=141&rft.issue=1&rft.spage=119&rft.epage=125&rft.pages=119-125&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-014-1778-0&rft_dat=%3Cproquest_cross%3E3543830721%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c442t-81ae9976973ae9826b19bf615e40970f72cf93953a69f302fce11060fd4184263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1641718881&rft_id=info:pmid/25037116&rfr_iscdi=true |